Biologics for hidradenitis suppurativa: evolution of the treatment paradigm

CA Maronese, C Moltrasio, G Genovese… - Expert Review of …, 2024 - Taylor & Francis
Introduction Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high
unmet need for effective medical management. Clinically, it is characterized by inflammatory …

Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data

F Martora, M Scalvenzi, T Battista… - Clinical, Cosmetic …, 2023 - Taylor & Francis
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …

[[Artículo traducido]] Revisión narrativa y actualización en fármacos biológicos y de pequeña molécula para el tratamiento de la hidradenitis supurativa: una entidad …

M Mansilla-Polo, B Escutia-Muñoz… - Actas Dermo …, 2023 - Elsevier
La hidradenitis supurativa (HS) es una entidad inflamatoria crónica caracterizada por la
aparición de múltiples nódulos, abscesos y fístulas, de predominio en regiones apocrinas …

Emerging treatments and the clinical trial landscape for hidradenitis suppurativa part I: topical and systemic medical therapies

NM Fragoso, R Masson, TJ Gillenwater, VY Shi… - Dermatology and …, 2023 - Springer
Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with
painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part …

Secukinumab in Hidradenitis Suppurativa patients who failed Adalimumab: A 52-week real-life study

F Martora, C Marasca, S Cacciapuoti… - Clinical, Cosmetic …, 2024 - Taylor & Francis
Background The treatment of hidradenitis suppurativa (HS) has always been a real
challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is …

Hidradenitis suppurativa in children and adolescents: an update on pharmacologic treatment options

N Chiang, C Sibbald, R Levy, I Lara-Corrales - Pediatric Drugs, 2023 - Springer
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that
manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin …

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

V Navarro-Compán, L Puig, S Vidal, J Ramírez… - Frontiers in …, 2023 - frontiersin.org
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F);
sequence homology is highest between IL-17A and IL-17F, displaying certain overlap** …

Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors

V Fang, R Gupta, RG Micheletti - Dermatologic Clinics, 2025 - derm.theclinics.com
Hidradenitis suppurativa (HS) is a chronic, relapsing, and debilitating inflammatory skin
disease with a profound impact on health-related quality of life. 1, 2 The disease burden of …

Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation

H Ben Abdallah, A Bregnhøj, L Iversen… - International Journal of …, 2023 - mdpi.com
Hidradenitis suppurativa is a chronic inflammatory skin disease with limited treatment
options. The poorly understood pathogenesis hinders the development of effective …

Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17/IL-23 axis in patients with Hidradenitis Suppurativa

A Tsiogka, AI Liakou, E Agiasofitou, S Gregoriou… - Dermatology, 2023 - karger.com
Background Paradoxical psoriasis (PP) has been mainly described in patients receiving
tumor necrosis factor-α (TNFα)-inhibitors for inflammatory bowel disease or psoriasis …